Glycemic Control and Cardiovascular Events in Diabetic Hemodialysis Patients

Author:

Drechsler Christiane1,Krane Vera1,Ritz Eberhard1,März Winfried1,Wanner Christoph1

Affiliation:

1. From the University Hospital Würzburg, Department of Medicine 1, Division of Nephrology, Würzburg, Germany (C.D., V.K., C.W.); Leiden University Medical Center, Department of Clinical Epidemiology, Leiden, the Netherlands (C.D.); University Hospital Heidelberg, Department of Medicine, Division of Nephrology, Heidelberg, Germany (E.R.); Synlab Center of Laboratory Diagnostics, Heidelberg, Germany (W.M.); Medical University of Graz, Clinical Institute of Medical and Chemical Laboratory Diagnostics,...

Abstract

Background— Patients on maintenance dialysis treatment experience an excess mortality, predominantly of sudden cardiac death. Poor glycemic control is associated with cardiovascular comorbidities in the general population. This study investigated the impact of glycemic control on cardiac and vascular outcomes in diabetic hemodialysis patients. Methods and Results— Glycohemoglobin A1c (HbA 1c ) was measured in 1255 hemodialysis patients with type 2 diabetes mellitus who participated in the German Diabetes and Dialysis Study (4D Study) and were followed up for a median of 4 years. Using Cox regression analyses, we determined hazard ratios to reach prespecified, adjudicated end points according to HbA 1c levels at baseline: sudden cardiac death (n=160), myocardial infarction (n=200), stroke (n=103), cardiovascular events (n=469), death caused by heart failure (n=41), and all-cause mortality (n=617). Patients had a mean age of 66±8 years (54% male) and mean HbA 1c of 6.7±1.3%. Patients with an HbA 1c >8% had a >2-fold higher risk of sudden death compared with those with an HbA 1c ≤6% (hazard ratio, 2.14; 95% confidence interval, 1.33 to 3.44), persisting in multivariate models. With each 1% increase in HbA 1c , the risk of sudden death rose significantly by 18%; similarly, cardiovascular events and mortality increased by 8%. There was a trend for higher risks of stroke and deaths resulting from heart failure, whereas myocardial infarction was not affected. The increased risks of both cardiovascular events and mortality were explained mainly by the impact of HbA 1c on sudden death. Conclusions— Poor glycemic control was strongly associated with sudden cardiac death in diabetic hemodialysis patients, which accounted for increased cardiovascular events and mortality. In contrast, myocardial infarction was not affected. Whether interventions achieving tight glycemic control decrease sudden death requires further evaluation. Clinical Trial Registration— URL: http://www.clinicalstudyresults.org. Unique identifier: CT-981–423–239.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference41 articles.

1. Renal replacement therapy in Europe: the results of a collaborative effort by the ERA–EDTA registry and six national or regional registries

2. US Renal Data System. USRDS 2008 Annual Data Report. Bethesda Md: National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases; 2008.

3. Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis

4. ERA-EDTA Registry. ERA-EDTA Registry 2005 Annual Report. Amsterdam Netherlands: Academic Medical Center Department of Medical Informatics; 2007.

5. Glycosylated Hemoglobin and the Risk of Microalbuminuria in Insulin-Dependent Diabetes Mellitus

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3